Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,461 to 1,480 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Expectant Management vs Elective Induction of Labor: deaths from any cause | 3 of 3,059 2 of 3,037 | 0.0 points -0.2 to 0.2 | 6,096 | NCT01990612 A Randomized Trial of Induction Versus Expectant Management |
| Expectant Management vs Elective Induction of Labor: Number of Participants Who Had Uterine Incisional Extension at Cesarean Delivery | 48 of 3,037 28 of 3,059 | 0.7 points 0.1 to 1.2 | 6,096 | NCT01990612 A Randomized Trial of Induction Versus Expectant Management |
| Expectant Management vs Elective Induction of Labor: serious adverse events | 3 of 3,037 2 of 3,059 | 0.0 points -0.2 to 0.2 | 6,096 | NCT01990612 A Randomized Trial of Induction Versus Expectant Management |
| Expectant Management vs Elective Induction of Labor: Number of Infants With Hyperbilirubinemia | 142 of 3,034 145 of 3,058 | -0.1 points -1.1 to 1.0 | 6,092 | NCT01990612 A Randomized Trial of Induction Versus Expectant Management |
| Fluarix Tetra vs mRNA-1010: Number of Participants With Unsolicited AEs | 749 of 3,048 800 of 3,035 | -1.8 points -4.0 to 0.4 | 6,083 | NCT05415462 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults |
| Fluarix Quadrivalent 60 ug vs mRNA-1010 50 ug: serious adverse events | 131 of 3,048 132 of 3,035 | -0.1 points -1.1 to 1.0 | 6,083 | NCT05415462 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults |
| Lixisenatide vs Placebo: Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina | 406 of 3,034 399 of 3,034 | 0.2 points -1.5 to 1.9 | 6,068 | NCT01147250 Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) |
| Lixisenatide vs Placebo: Time to First Occurence of CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke, Hospitalization for Unstable Angina or Hospitalization For Heart Failure | 456 of 3,034 469 of 3,034 | -0.4 points -2.2 to 1.4 | 6,068 | NCT01147250 Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) |
| Lixisenatide vs Placebo: Time to First Occurence of CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke, Hospitalization for Unstable Angina, Hospitalization For Heart Failure or Coronary Revascularization Procedure | 661 of 3,034 659 of 3,034 | 0.1 points -2.0 to 2.1 | 6,068 | NCT01147250 Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) |
| Pre-Intervention vs Post-Intervention: Individuals With an Intravenous Line | 2,004 of 3,243 2,056 of 2,823 | -11.0 points -13.4 to -8.7 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Individuals With a Nasogastric Tube | 1,293 of 3,243 922 of 2,823 | 7.2 points 4.8 to 9.6 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Individuals With an Order for Benzodiazepine Medication | 1,102 of 3,243 1,185 of 2,823 | -8.0 points -10.4 to -5.5 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Individuals Who Received Benzodiazepine Medication | 710 of 3,243 675 of 2,823 | -2.0 points -4.1 to 0.1 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Individuals With an Order for Antipsychotic Medication | 336 of 3,243 661 of 2,823 | -13.1 points -14.9 to -11.2 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Individuals With an Advance Directive | 1,194 of 3,243 1,306 of 2,823 | -9.4 points -11.9 to -7.0 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Number of Individuals Who Died in Restraints | 531 of 3,243 362 of 2,823 | 3.6 points 1.8 to 5.3 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Individuals With a Palliative Care Consultation | 184 of 3,243 885 of 2,823 | -25.7 points -27.6 to -23.8 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-intervention: Individuals Administered of Opioid Medication | 1,569 of 3,243 1,662 of 2,823 | -10.5 points -13.0 to -8.0 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Individuals Who Received Scopolamine | 113 of 3,243 633 of 2,823 | -18.9 points -20.6 to -17.3 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Number of Patients Who Died in ICU | 1,312 of 3,243 1,046 of 2,823 | 3.4 points 0.9 to 5.9 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=74
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01990612-deaths",
"title": "Expectant Management vs Elective Induction of Labor: deaths from any cause",
"summary": "3 of 3059 against 2 of 3037; risk difference 0.0 points, 95% interval -0.2 to 0.2; NCT01990612, A Randomized Trial of Induction Versus Expectant Management",
"record": "/library/comparisons/NCT01990612-deaths",
"nct_id": "NCT01990612",
"kind": "deaths",
"participants": 6096,
"risk_difference": {
"value": 0.0003221680347954395,
"lower": -0.001533854617283841,
"upper": 0.0022802706230753323
},
"group_1": "3 of 3,059",
"group_2": "2 of 3,037",
"difference": "0.0 points",
"interval": "-0.2 to 0.2",
"trial_title": "A Randomized Trial of Induction Versus Expectant Management"
},
{
"id": "NCT01990612-ebb09a66",
"title": "Expectant Management vs Elective Induction of Labor: Number of Participants Who Had Uterine Incisional Extension at Cesarean Delivery",
"summary": "48 of 3037 against 28 of 3059; risk difference 0.7 points, 95% interval 0.1 to 1.2; NCT01990612, A Randomized Trial of Induction Versus Expectant Management",
"record": "/library/comparisons/NCT01990612-ebb09a66",
"nct_id": "NCT01990612",
"kind": "outcome",
"participants": 6096,
"risk_difference": {
"value": 0.006651752715743061,
"lower": 0.0010589838109953164,
"upper": 0.012464271301226883
},
"group_1": "48 of 3,037",
"group_2": "28 of 3,059",
"difference": "0.7 points",
"interval": "0.1 to 1.2",
"trial_title": "A Randomized Trial of Induction Versus Expectant Management"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=75",
"request_id": "jLUNAAlmAnVZyrgO"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant